All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @legertreatments on TikTok · 23s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @legertreatments's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I'm worried about losing my hair on TRT. Any advice?
  2. 0:03I think I'm the wrong person to ask this question.
  3. 0:05It can happen. Testosterone converts into dihydrotestosterone, which can kind of speed
  4. 0:13up or exacerbate male pattern baldness. Just be cautious about using medications like
  5. 0:18finasteride because that can have implications for your testosterone treatment.

TRT and hair loss: what the evidence actually shows

Leger Treatments

TikTok creator

1.5K viewsWatch on TikTok

Quick answer

TRT increases circulating testosterone, which elevates the substrate available for 5-alpha reductase conversion to DHT, a potent androgen that accelerates follicular miniaturization in genetically predisposed men. The degree of DHT elevation depends partly on delivery method, with transdermal formulations generally producing higher DHT-to-testosterone ratios than intramuscular injections. Finasteride can mitigate DHT-related hair loss but requires monitoring on TRT because inhibiting 5-alpha reductase shifts testosterone availability toward aromatization, potentially elevating estradiol.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For TRT and hair loss: what the evidence actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

TRT and hair loss: what the evidence actually shows should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "TRT and hair loss: what the evidence actually shows" from Leger Treatments. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: TRT increases circulating testosterone, which elevates the substrate available for 5-alpha reductase conversion to DHT, a potent androgen that accelerates follicular miniaturization in genetically predisposed men.

The reason this review is not generic is the source wording and the canonical claim label "trt does trt cause hair loss it s a common question we get asked." In this clip, the useful excerpt is: "I'm worried about losing my hair on TRT." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Genetic predisposition is the key variable.
People who land here are usually comparing the Testosterone claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

TRT increases circulating testosterone, which elevates the substrate available for 5-alpha reductase conversion to DHT, a potent androgen that accelerates follicular miniaturization in genetically predisposed men.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • TRT increases circulating testosterone, which elevates the substrate available for 5-alpha reductase conversion to DHT, a potent androgen that accelerates follicular miniaturization in genetically predisposed men. The degree of DHT elevation depends partly on delivery method, with transdermal formulations generally producing higher DHT-to-testosterone ratios than intramuscular injections. Finasteride can mitigate DHT-related hair loss but requires monitoring on TRT because inhibiting 5-alpha reductase shifts testosterone availability toward aromatization, potentially elevating estradiol.
  • DHT, not testosterone itself, is the primary driver of androgenetic alopecia. TRT raises testosterone levels, which increases available substrate for DHT conversion via 5-alpha reductase.
  • Genetic predisposition is the key variable. Men without family history of pattern baldness face substantially lower risk of TRT-accelerated hair loss.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • DHT, not testosterone itself, is the primary driver of androgenetic alopecia. TRT raises testosterone levels, which increases available substrate for DHT conversion via 5-alpha reductase.
  • Genetic predisposition is the key variable. Men without family history of pattern baldness face substantially lower risk of TRT-accelerated hair loss.
  • Delivery method affects DHT levels. A 2010 Swerdloff et al. study (Journal of Clinical Endocrinology and Metabolism) found transdermal testosterone produces higher DHT-to-testosterone ratios than intramuscular injections.
  • Finasteride blocks DHT but increases estradiol conversion on TRT. Any addition of finasteride to a TRT protocol should involve estradiol monitoring and prescriber oversight.
  • Topical finasteride may offer a lower systemic-exposure option for hair retention. Randolph and Bhatt (2021, Journal of Drugs in Dermatology) reviewed topical formulations as potentially safer for men on hormonal therapy.
  • The FDA updated finasteride labeling in 2012 to include persistent sexual side effects. This is part of the risk conversation that should happen before adding it to any TRT protocol.
  • The creator's core claim that TRT accelerates rather than directly causes hair loss is supported by the literature. The finasteride warning was correct in direction but needed more clinical detail to be genuinely useful.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @legertreatments actually say?

The creator acknowledged that hair loss on TRT "can happen" and correctly pointed to the conversion of testosterone into dihydrotestosterone (DHT) as the mechanism. They also flagged finasteride as something to be cautious about, saying it "can have implications for your testosterone treatment." That last point is where things get genuinely interesting, and somewhat incomplete.

To their credit, the creator didn't oversell the risk or promise hair loss is inevitable. The framing was cautious and hedged. But the finasteride warning was left hanging without real explanation, which could leave viewers either too scared to consider it or completely confused about why it matters.

Does the science back this up?

Yes, mostly. The DHT pathway is well-established. Testosterone is converted to DHT by the enzyme 5-alpha reductase, primarily in hair follicles and the prostate. In men genetically predisposed to androgenetic alopecia, DHT binds to androgen receptors in scalp follicles and triggers miniaturization over time. This is not controversial.

What TRT does is increase circulating testosterone, which means more substrate available for that conversion. A 2016 review by Blumeyer et al. in the Journal of the German Society of Dermatology confirmed that elevated androgens can accelerate genetically predisposed hair loss, but do not cause it in men without the genetic predisposition. So "accelerate" is the right word. The creator used it correctly.

The wrinkle is that DHT levels on TRT vary significantly depending on the delivery method. A 2010 study by Swerdloff et al. published in the Journal of Clinical Endocrinology and Metabolism found that testosterone gels produce higher DHT-to-testosterone ratios than injections, which is a clinically meaningful difference for men worried about scalp effects.

What did they get wrong (or right)?

The DHT explanation was accurate. Credit where it is due. But the finasteride comment deserves more scrutiny. The creator said to "be cautious" because finasteride "can have implications for your testosterone treatment." That is technically true but so vague it is almost misleading by omission.

Here is what actually happens: finasteride blocks 5-alpha reductase, which reduces DHT but also shifts the testosterone-to-estrogen ratio. When DHT conversion is inhibited, more testosterone becomes available for aromatization into estradiol. For men on TRT, this can mean elevated estrogen levels, which carries its own set of side effects including water retention, mood changes, and in some cases gynecomastia. That is the "implication" the creator was gesturing at. Saying it plainly would have been more useful than the vague caution.

There is also a broader concern worth naming. The Post-Finasteride Syndrome debate, while still contested in the literature, has been reported in case series and has a dedicated registry. The FDA updated finasteride labeling in 2012 to include persistent sexual side effects. Dismissing finasteride as simply having "implications for testosterone treatment" undersells a legitimate risk profile that patients deserve to understand fully.

What should you actually know?

If you are on TRT and worried about hair loss, a few things are worth understanding before your next appointment.

  • Your genetic predisposition matters more than your TRT dose. If you have no family history of androgenetic alopecia, elevated testosterone is unlikely to trigger significant hair loss.
  • DHT levels on TRT are not uniform. Delivery method matters. Gels and creams tend to produce higher DHT relative to testosterone than intramuscular injections. If hair retention is a priority, this is worth discussing with your prescriber.
  • Finasteride is not automatically off the table on TRT, but it requires careful monitoring of estradiol and testosterone levels. It should not be added without clinical oversight and regular bloodwork.
  • Topical finasteride and topical minoxidil have emerging evidence for preserving hair with lower systemic absorption, which may reduce the hormonal interaction risk. A 2021 study by Randolph and Bhatt in the Journal of Drugs in Dermatology reviewed topical finasteride as a lower-risk option for men on hormonal therapy.

The creator's instinct to flag finasteride was correct. The execution left too much unsaid for a patient trying to make an informed decision.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Leger Treatments · TikTok creator

1.5K views on this video

Does TRT cause hair loss? 💉💬   It’s a common question we get asked from patients considering Testosterone Replacement Therapy (TRT).   💡 The short answer: TRT doesn’t directly cause hair loss — but it can accelerate it in those who are genetically predisposed to male pattern baldness.   This happens due to increased levels of DHT, a hormone derived from testosterone that can impact hair follicles.   Have more TRT-related questions? Drop them in the comments — we’re here to help. 👇 #trt #tes

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about dht, not testosterone itself,?

DHT, not testosterone itself, is the primary driver of androgenetic alopecia. TRT raises testosterone levels, which increases available substrate for DHT conversion via 5-alpha reductase.

What does the video say about genetic predisposition?

Genetic predisposition is the key variable. Men without family history of pattern baldness face substantially lower risk of TRT-accelerated hair loss.

What does the video say about delivery method affects dht levels. a 2010 swerdloff et al.?

Delivery method affects DHT levels. A 2010 Swerdloff et al. study (Journal of Clinical Endocrinology and Metabolism) found transdermal testosterone produces higher DHT-to-testosterone ratios than intramuscular injections.

What does the video say about finasteride blocks dht?

Finasteride blocks DHT but increases estradiol conversion on TRT. Any addition of finasteride to a TRT protocol should involve estradiol monitoring and prescriber oversight.

What does the video say about topical finasteride may offer a lower systemic-exposure option for hair?

Topical finasteride may offer a lower systemic-exposure option for hair retention. Randolph and Bhatt (2021, Journal of Drugs in Dermatology) reviewed topical formulations as potentially safer for men on hormonal therapy.

What does the video say about the fda updated finasteride labeling in 2012 to include persistent?

The FDA updated finasteride labeling in 2012 to include persistent sexual side effects. This is part of the risk conversation that should happen before adding it to any TRT protocol.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Not medical advice. This video was made by Leger Treatments, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.